In approximately 63% of patients with breast cancer related to the pathogenic variant BRCA1 or BRCA2, genetic testing was performed after surgery of the primary cancer, with 62% of these patients also undergoing a primary breast-conserving treatment (BCT) [3]. This evidence concerns the gene BRCA2 and breast carcinoma.